Chardan Capital Issues Optimistic Forecast for COYA Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA - Free Report) - Analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of Coya Therapeutics in a note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the company will post earnings of ($1.03) per share for the year, up from their prior estimate of ($1.26). Chardan Capital has a "Buy" rating and a $14.00 price objective on the stock. The consensus estimate for Coya Therapeutics' current full-year earnings is ($1.15) per share.

Separately, D. Boral Capital reaffirmed a "buy" rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Thursday.

Coya Therapeutics Price Performance

Shares of COYA traded down $0.01 on Thursday, reaching $6.56. The company's stock had a trading volume of 14,959 shares, compared to its average volume of 91,406. The stock has a market capitalization of $109.63 million, a P/E ratio of -10.08 and a beta of 0.31. Coya Therapeutics has a 12-month low of $4.75 and a 12-month high of $10.24. The stock's 50 day simple moving average is $6.43 and its two-hundred day simple moving average is $6.52.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, beating analysts' consensus estimates of ($0.32) by $0.14. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $0.10 million.

Hedge Funds Weigh In On Coya Therapeutics

Hedge funds have recently modified their holdings of the stock. DME Capital Management LP increased its holdings in Coya Therapeutics by 29.2% in the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company's stock valued at $9,434,000 after acquiring an additional 372,414 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Coya Therapeutics during the fourth quarter valued at about $74,000. Northern Trust Corp increased its holdings in shares of Coya Therapeutics by 12.2% in the fourth quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after purchasing an additional 3,099 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Coya Therapeutics by 1,005.7% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company's stock worth $30,000 after buying an additional 4,777 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Coya Therapeutics during the fourth quarter valued at approximately $59,000. Hedge funds and other institutional investors own 39.75% of the company's stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.